The indications and safety of polyvalent immunoglobulin for post-exposure prophylaxis of hepatitis A, rubella and measles

References

• Niewiesk S. Maternal antibodies: clinical significance, mechanism of interference with immune responses, and possible vaccination strategies. Front Immunol. 2014;5:1–15. doi:10.3389/fimmu.2014.00001.
   PubMed Web of Science ®Google Scholar
• Zingher A, Mortimer P. Convalescent whole blood, plasma and serum in the prophylaxis of measles: JAMA, 12 April, 1926; 1180–1187. Rev Med Virol. 2005;15:407–18. doi:10.1002/rmv.480.
   PubMed Web of Science ®Google Scholar
• WHO. Annex 4: recommendations for the production, control and regulation of human plasma for fractionation. In: WHO, editor. WHO technical report series; Geneva, Switzerland: World Health Organization 2007;189–264.
   Google Scholar
• Burnouf T. Modern plasma fractionation. Transfus Med Rev. 2007;21:101–17. doi:10.1016/j.tmrv.2006.11.001.
   PubMed Web of Science ®Google Scholar
• Burnouf T. An overview of plasma fractionation. Annals Blood. 2018;3:1–10.
   Google Scholar
• Australian Technical Advisory Group on Immunisation. Australian immunisation handbook. Canberra, Australia: Australian Government Department of Health; 2018.
   Google Scholar
• Ashwell M. Normal immunoglobulin (human): indications and safety. NSW Public Health Bull. 1997;8:84–85. doi:10.1071/NB97032.
   Google Scholar
• Hotchko M, Robert P. Recent market status and trends of fractionated plasma products. Annals Blood. 2018;3:1–6. doi:10.21037/aob.2018.01.06.
   Google Scholar
• Communicable Diseases Network Australia. Hepatitis A: national guidelines for public health units. Canberra, Australia: Commonwealth Department of Health; 2018.
   Google Scholar
• Communicable Diseases Network Australia. Measles: national guidelines for public health units. Canberra, Australia: Commonwealth Department of Health; 2015.
   Google Scholar
• Centers for Disease Control and Prevention. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the advisory committee on immunization practices (ACIP). MMWR - Morbidity Mortality Weekly Rep 2013;62:1–34.
   PubMed Web of Science ®Google Scholar
• Public Health Agency of Canada. Canadian immunization guide: part 5 - passive immunization. Ontario, Canada: Government of Canada; 2017.
   Google Scholar
• Fleurant-Ceelen A, Tunis M, House A. National committee on immunization. What is new in the Canadian immunization guide: November 2016 to November 2018. Can Commun Dis Rep. 2018;44:351–55. doi:10.14745/ccdr.v44i12a06.
   Google Scholar
• Public Health England. Guidelines on post-exposure prophylaxis for measles August 2017. London (England): Public Health England; 2017.
   Google Scholar
• Public health England. Immunoglobulin Handbook: hepatitis A. London (United Kingdom): Public Health England; 2017.
   Google Scholar
• Nelson N, Link-Gelles R, Hofmeister M, Romero J, Moore K, Ward J, Schillie SF. Update: recommendations of the advisory committee on immunization practices for use of hepatitis a vaccine for postexposure prophylaxis and for preexposure prophylaxis for international travel. MMWR - Morbidity Mortality Weekly Rep. 2018;67:1216–20. doi:10.15585/mmwr.mm6743a5.
   PubMed Web of Science ®Google Scholar
• Mearkle R, Bologun K, Edelstein M, Homer K, Keel P, Mandal S, Ngui, SL. Public health control and management of hepatitis A. London, UK: Public Health England; 2017.
   Google Scholar
• UK Department of Health. Rubella: the green book, chapter 28. Immunisation against infectious disease - “The Green Book”. London, UK: Department of Health; 2013.
   Google Scholar
• New Zealand Ministry of Health. Immunisation Handbook 2017 2nd. Wellington (New Zealand): Ministry of Health; 2018.
   Google Scholar
• CSL Behring.Product information: Normal Immunoglobulin-VF 2017. Available from: https://www.cslbehring.com.au/-/media/cslb-australia/documents/aus-pis-and-cmis/normal-immunoglobulin-au-pi-900.pdf?la=en-us&hash=48E460BA88375592764C0AECF0083C074322AABB
   Google Scholar
• Cherin P, Marie I, Michallet M, Pelus E, Dantal J, Crave J, Delain J-C, Viallard J-F. Management of adverse events in the treatment of patients with immunoglobulin therapy: a review of evidence. Autoimmun Rev. 2016;15:71–81. doi:10.1016/j.autrev.2015.09.002.
   PubMed Web of Science ®Google Scholar
• Bonilla F. Intravenous immunoglobulin: adverse reactions and management. J Allergy Clin Immunol. 2008;122:1238–39. doi:10.1016/j.jaci.2008.08.033.
   PubMed Web of Science ®Google Scholar
• Stiehm E. Adverse effects of human immunoglobulin therapy. Transfus Med Rev. 2013;27:171–78. doi:10.1016/j.tmrv.2013.05.004.
   PubMed Web of Science ®Google Scholar
• Australian Red Cross Blood Service. Residual risk estimates for transfusion-transmissible infections 2018. [ accessed 2018 Mar 27]. https://transfusion.com.au/adverse_events/risks/estimates.
   Google Scholar
• Young M, Faddy H, Fryk J, Nimmo G, Cripps A. Hepatitis A virus antibodies in Australian blood donors: implications for immunoglobulin sufficiency. Vaccine. 2015;33:5135–39. doi:10.1016/j.vaccine.2015.08.003.
   PubMed Web of Science ®Google Scholar
• Nelson N. Updated dosing instructions for immune globulin (Human) GamaSTAN S/D for hepatitis a virus prophylaxis. MMWR - Morbidity Mortality Weekly Rep. 2017;66:959–60. doi:10.15585/mmwr.mm6636a5.
   PubMed Web of Science ®Google Scholar
• Public Health Agency of Canada. Canadian Immunization Guide: Part. 4 - active vaccines - hepatitis a vaccine. Ontario, Canada: Government of Canada; 2018.
   Google Scholar
• Royal College of Paediatrics and Child Health. UK-WHO growth charts – 2–18 years 2012. [accessed 2019 Apr 21]. https://www.rcpch.ac.uk/resources/uk-who-growth-charts-2-18-years.
   Google Scholar
• Young M, Cripps A. Passive immunization for the public health control of communicable diseases: current status in four high-income countries and where to next. Hum Vaccines Immunotherapeutics. 2013;9:1885–93. doi:10.4161/hv.25311.
   PubMed Web of Science ®Google Scholar
• Public Health Agency of Canada. Canadian immunization guide: table of updates [accessed 2019 Mar 20]. https://www.canada.ca/en/public-health/services/canadian-immunization-guide/updates.html.
   Google Scholar
• Centers for Disease Control and Prevention. Control and prevention of rubella: evaluation and management of suspected outbreaks, rubella in pregnant women, and surveillance for congenital rubella syndrome. MMWR - Morbidity Mortality Weekly Rep 2001;50:1–23.
   PubMedGoogle Scholar
• Public Health Agency of Canada. Canadian immunization guide: part 4 - active immunization - rubella vaccine. Ontario, Canada: Government of Canada; 2018.
   Google Scholar
• Public Health Agency of Canada. Canadian immunization guide: part 4 - active vaccines - measles vaccine. Ontario, Canada: Government of Canada; 2018.
   Google Scholar
• Amirthalingam G, Brown K, le Polain O, Ramsay M. PHE national measles guidelines. London (England): Public Health England; 2017.
   Google Scholar
• Tunis M, Salvadori M, Dubey V, Baclic O. on behalf of the national advisory committee on immunization. Updated NACI recommendation for measles post-exposure prophylaxis. Can Commun Dis Rep. 2018;44:226–30. doi:10.14745/ccdr.v44i09a07.
   PubMedGoogle Scholar
• Public Health Agency of Canada. Contents of immunizing agents available for use in Canada. [updated 2018 Jan 30]. https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-1-key-immunization-information/page-15-contents-immunizing-agents-available-use-canada.html.
   Google Scholar
• Canadian Blood Services. Intravenous immune globulins [accessed 2018 March 20]. https://blood.ca/sites/default/files/Intravenous_Immune_Globulins_Table.pdf.
   Google Scholar
• Grifols Therapeutics Inc. Product monograph: gamaSTAN S/D. [accessed 2018 Feb 6]. https://www.grifols.com/documents/17006/133313/GamaSTAN-SD-en.pdf/8166db44-8ec4-44a2-8fa5-f37bcafbf8e6.
   Google Scholar
• Grifols Therapeutics Inc. Product monograph: iVIGnex. [accessed 2017 July 12]. https://www.grifols.com/documents/17006/133313/igivnex-ca-en.pdf/f3121cb8-46ac-4e0e-9828-dfe23bff4f69.
   Google Scholar
• Shire Pharma Canada ULC. Product monograph: gammagard Liquid. [accessed 2018 May 4]. Available from: https://www.shirecanada.com/-/media/shire/shireglobal/shirecanada/pdffiles/product%20information/gammagard-liquid-pm-en.pdf.
   Google Scholar
• Shire Pharma Canada ULC. Product monograph: gammagard S/D. [accessed 2018 Jul 13]. https://www.shirecanada.com/-/media/shire/shireglobal/shirecanada/pdffiles/product%20information/gammagard-sd-pm-en.pdf.
   Google Scholar
• Grifols Therapeutics Inc. Product monograph: gamunex. [accessed 2013 Jan 29 ; cited 22 April 2019]. https://www.grifols.com/documents/17006/186428/gamunex-en.pdf/3fd763d1-1b44-467c-b8e0-d9892db8ec0a.
   Google Scholar
• Octapharma. Product monograph: panzyga [accessed 2019 Aug 29]. https://www.octapharma.ca/fileadmin/user_upload/octapharma.ca/Product_Monographs/PANZYGA-PM-EN.pdf.
   Google Scholar
• NZ Blood. Immunoglobulins. [ accessed 2017 Mar 7]. https://www.nzblood.co.nz/clinical-information/transfusion-medicine/health-professionals-medicine-datasheets/immunoglobulins/.
   Google Scholar
• Datapharm. Medicines compendium (eMC): search results for immunoglobulin - summaries of product characteristics. Surrey, United Kingdom [ accessed 2019 April 22]. https://www.medicines.org.uk/emc/search?q=immunoglobulin.
   Google Scholar
• US Food and Drug Administration. Vaccines, blood & biologics: immune globulins - package inserts. [accessed 2019 Feb 7. https://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/ucm127589.htm.
   Google Scholar
• Young M, Bertolini J, Kotharu P, Maher D, Cripps A. Do Australian immunoglobulin products meet international measles antibody titre standards? Hum Vaccines Immunotherapeutics. 2016;13(3):607–12. doi:10.1080/21645515.2016.1234554.
   PubMed Web of Science ®Google Scholar
• Young M, Bertolini J, Kotharu P, Maher D, Cripps A. Rubella antibodies in Australian immunoglobulin products. Hum Vaccin Immunother. 2017 June 12;13(8):1952–55. published online. doi:10.1080/21645515.2017.1327110.
   PubMed Web of Science ®Google Scholar
• Young M, Nimmo G, Cripps A, Jones M. Post-exposure passive immunisation for preventing measles. Cochrane Database Syst Rev. 2014;(4). Art. No: CD010056. doi:10.1002/14651858.CD010056.pub2.
   Web of Science ®Google Scholar
• Tejada-Strop A, Costafreda M, Dimitrova Z, Kaplan G, Teo C. Evaluation of potencies of immune globulin products against hepatitis A. JAMA Intern Med. 2017;177:430–32. doi:10.1001/jamainternmed.2016.9057.
   PubMed Web of Science ®Google Scholar
• Young M, Cripps A, Nimmo G, van Driel M. Post-exposure passive immunisation for preventing rubella and congenital rubella syndrome. Cochrane Database Syst Rev. 2015;(9). Art. No.: CD010586. doi:10.1002/14651858.CD010586.pub2.
   Web of Science ®Google Scholar
• Young M, Ng S, Nimmo G, Cripps A. The optimal dose of disease-specific antibodies for post-exposure prophylaxis of measles and rubella in Australia: new guidelines recommended. Expert Opin Drug Metab Toxicol. 2018;14:663–69. doi:10.1080/17425255.2018.1484449.
   PubMed Web of Science ®Google Scholar